Third, we did not confirm the biomarkers findings from the LUX-Head and Neck 1 trial27, which demonstrated a higher efficacy of afatinib in p16-negative, EGFR-amplified, HER3-low, and PTEN-high HNSCC patients. The gene discussed is CDKN2A; the disease is head and neck squamous cell carcinoma.